A randomised-controlled Phase I de-escalation trial of Molnupiravir and Nirmatrelvir/Ritonavir combination for mild-moderate SARS-CoV-2 infection
Khoo et al., medRxiv, doi:10.1101/2025.05.01.25326797
https://c19early.org/khoo3pl.html